幽门螺旋杆菌感染的诊治进展(5)
[23] Leal YA，Cedillo-Rivera R，Simón JA.Utility of stool sample-based tests for the diagnosis of Helicobacter pylori infection in children[J].J Pediatr Gastroenterol Nutr，2011，52(6)：718-728.
[24] Sugimoto M，Yamaoka Y.Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy[J].Arch Immunol Ther Exp (Warsz)，2009，57(1)：45-56.
[25] Uemura N，Okamoto S，Yamamoto S.Helicobacter pylori infection and the development of gastric cancer[J].N Engl J Med，2001，345(11)： 84-789.
, 百拇医药
[26] Mégraud F.Current recommendations for Helicobacter pylori therapies in a world of evolving resistance[J].Gut Microbes，2013，4(6)：Epub ahead of print.
[27] Megraud F.Helicobacter pylori and antibiotic resistance[J].Gut，2007，56(11)：1502.
[28] Gisbert JP，de la Morena F，Abraira V.Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection：a systematic review and meta-analysis[J].Am J Gastroenterol，2006，101(8)：1921-1930.
, 百拇医药
[29] Malfertheiner P，Megraud F，O’Morain CA. Management of Heli-cobacter pylori infection--the Maastricht IV/ Florence Consensus Report[J].Gut，2012，61(5)：646-664.
[30] Malfertheiner P，Mégraud F，O’Morain C.Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report[J].Aliment Pharmacol Ther，2002，16(2)：167-180.
[31] Loyd RA，McClellan DA.Update on the evaluation and management of functional dyspepsia.Am Fam Physician[J]，2011，83(5)：547-552.
, 百拇医药
[32] Furuta T，Sugimoto M， Shirai N.Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole， amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H.pylori[J].Aliment Pharmacol Ther，2007，26(5)：693-703.
[33] Szajewska H，Horvath A，Piwowarczyk A.Meta-analysis：the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment[J].Aliment Pharmacol Ther，2010，32(9)：1069-1079.
, 百拇医药
[34] Stenstrom B，Mendis A，Marshall B. Helicobacter pylori--the latest in diagnosis and treatment[J].Aust Fam Physician， 2008，37(8)：608-612.
[35] McColl KE.Clinical practice.Helicobacter pylori infection[J].N Engl J Med，2010，362(17)：1597-1604.
[36] De Francesco V，Giorgio F，Hassan C.pylori antibiotic resistance： a systematic review[J].J Gastrointestin Liver Dis，2010，19(4)：409-414.
[37] Sardarian H，Fakheri H，Hosseini V.Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran：a prospective randomized trial[J].Helicobacter，2013，18(2)：129-134.
, 百拇医药
[38] Zullo A，Scaccianoce G，De Francesco V.Concomitant，sequential，and hybrid therapy for H. pylori eradication：a pilot study[J].Clin Res Hepatol Gastroenterol，2013，37(6)：647-650.
[39] Gisbert JP，Morena F.Systematic review and meta-analysis：levofloxacin-based rescue regimens after Helicobacter pylori treatment failure[J].Aliment Pharmacol Ther，2006，23(1)：35-44.
[40] Morgan DR，Torres J，Sexton R.Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities[J].JAMA，2013，309(6)：578-586.
, 百拇医药
[41] Malik R，Guleria K，Kaur I.Effect of Helicobacter pylori eradication therapy in iron deiciency anaemia of pregnancy-a pilot study[J].Indian J Med Res，2011，134(8)：224-231.
[42] Ahmad K，Fatemeh F，Mehri N.Probiotics for the treatment of pediatric helicobacter pylori infection：a randomized double blind clinical trial[J].Iran J Pediatr，2013，23(1)：79-84., 百拇医药(路晓明)
[24] Sugimoto M，Yamaoka Y.Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy[J].Arch Immunol Ther Exp (Warsz)，2009，57(1)：45-56.
[25] Uemura N，Okamoto S，Yamamoto S.Helicobacter pylori infection and the development of gastric cancer[J].N Engl J Med，2001，345(11)： 84-789.
, 百拇医药
[26] Mégraud F.Current recommendations for Helicobacter pylori therapies in a world of evolving resistance[J].Gut Microbes，2013，4(6)：Epub ahead of print.
[27] Megraud F.Helicobacter pylori and antibiotic resistance[J].Gut，2007，56(11)：1502.
[28] Gisbert JP，de la Morena F，Abraira V.Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection：a systematic review and meta-analysis[J].Am J Gastroenterol，2006，101(8)：1921-1930.
, 百拇医药
[29] Malfertheiner P，Megraud F，O’Morain CA. Management of Heli-cobacter pylori infection--the Maastricht IV/ Florence Consensus Report[J].Gut，2012，61(5)：646-664.
[30] Malfertheiner P，Mégraud F，O’Morain C.Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report[J].Aliment Pharmacol Ther，2002，16(2)：167-180.
[31] Loyd RA，McClellan DA.Update on the evaluation and management of functional dyspepsia.Am Fam Physician[J]，2011，83(5)：547-552.
, 百拇医药
[32] Furuta T，Sugimoto M， Shirai N.Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole， amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H.pylori[J].Aliment Pharmacol Ther，2007，26(5)：693-703.
[33] Szajewska H，Horvath A，Piwowarczyk A.Meta-analysis：the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment[J].Aliment Pharmacol Ther，2010，32(9)：1069-1079.
, 百拇医药
[34] Stenstrom B，Mendis A，Marshall B. Helicobacter pylori--the latest in diagnosis and treatment[J].Aust Fam Physician， 2008，37(8)：608-612.
[35] McColl KE.Clinical practice.Helicobacter pylori infection[J].N Engl J Med，2010，362(17)：1597-1604.
[36] De Francesco V，Giorgio F，Hassan C.pylori antibiotic resistance： a systematic review[J].J Gastrointestin Liver Dis，2010，19(4)：409-414.
[37] Sardarian H，Fakheri H，Hosseini V.Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran：a prospective randomized trial[J].Helicobacter，2013，18(2)：129-134.
, 百拇医药
[38] Zullo A，Scaccianoce G，De Francesco V.Concomitant，sequential，and hybrid therapy for H. pylori eradication：a pilot study[J].Clin Res Hepatol Gastroenterol，2013，37(6)：647-650.
[39] Gisbert JP，Morena F.Systematic review and meta-analysis：levofloxacin-based rescue regimens after Helicobacter pylori treatment failure[J].Aliment Pharmacol Ther，2006，23(1)：35-44.
[40] Morgan DR，Torres J，Sexton R.Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities[J].JAMA，2013，309(6)：578-586.
, 百拇医药
[41] Malik R，Guleria K，Kaur I.Effect of Helicobacter pylori eradication therapy in iron deiciency anaemia of pregnancy-a pilot study[J].Indian J Med Res，2011，134(8)：224-231.
[42] Ahmad K，Fatemeh F，Mehri N.Probiotics for the treatment of pediatric helicobacter pylori infection：a randomized double blind clinical trial[J].Iran J Pediatr，2013，23(1)：79-84., 百拇医药(路晓明)